Coronary disease & ACS

Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2)

Am Heart JPublished investigator-initiated, multicenter, randomized controlled trial

Study context

Population
Patients using direct oral anticoagulation (DOAC) and scheduled for elective invasive coronary angiography (ICA) or percutaneous coronary intervention (PCI)planned number to be randomized
Participants
1,270 patients
Planned comparison
Continuing DOAC therapy vs temporary interruption
Primary endpoint
In-hospital bleeding, Bleeding Academic Research Consortium (BARC) type 2, 3, or 5
Follow-up
In-hospital
Methodological detailsdesign and rationale (protocol), 1:1 randomization
  • Design and rationale (protocol)
  • 1:1 randomization

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

Direct oral anticoagulation interruption vs continuation in patients undergoing elective invasive coronary angiography or percutaneous coronary intervention: Design and rationale of the South Limburg Myocardial Infarction Study Group Trial 2 (SLIM-2). Am Heart J. Published 27 April 2026. doi:10.1016/j.ahj.2026.107462

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.